4.5 Article

Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 85, 期 4, 页码 1519-1528

出版社

IOS PRESS
DOI: 10.3233/JAD-215091

关键词

Alzheimer's disease; apolipoprotein E4; cholesterol; dementia; lipid metabolism

资金

  1. Summer Graduate Research Fellowship through the University of Wisconsin -Milwaukee
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]
  3. DODADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. BristolMyers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  24. Johnson & Johnson Pharmaceutical Research & Development LLC.
  25. Lumosity
  26. Lundbeck
  27. Merck Co., Inc.
  28. Meso Scale Diagnostics, LLC.
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer Inc.
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research
  38. Genentech, Inc.

向作者/读者索取更多资源

This study investigates the relationship between total cholesterol and APOE-related AD risk. The results show that higher total cholesterol may be a significant contributor to AD risk, particularly in APOE4 carriers. These findings highlight a possible mechanism by which APOE confers AD risk and indicate the potential for AD risk modification through maintenance of healthy total cholesterol levels.
Background: APOE epsilon 4 allele confers greatest genetic risk for Alzheimer's disease (AD), yet mechanisms underlying this risk remain elusive. APOE is involved in lipid metabolism, and literature suggest relationships between high total cholesterol, APOE, and AD. Further investigation is needed to elucidate the potential role of total cholesterol in AD risk. Objective: To investigate the relationship between total cholesterol and APOE-related AD risk in the Alzheimer's Disease Neuroimaging Initiative. Methods: Participants (N = 1,534) were classified as controls (cognitively normal; N = 404), early mild cognitive impairment (MCI; N = 294), late MCI (N = 539), or AD (N = 297). Total cholesterol levels were compared across APOE genotype and diagnosis. Mendelian randomization was performed to examine causality between total cholesterol and AD risk using APOE as a genetic instrument. Results: Total cholesterol was higher in APOE4+ compared to APOE3 and APOE2+ (ps < 0.04) carriers. Those with AD and late MCI (ps <0.001) had higher total cholesterol than the control group. Comparing APOE4+ to APOE3 carriers, the predicted odds ratios per mg/dL greater total cholesterol were 1.11 for MCI (95% confidence interval, 1.04-7.32), 1.05 for early MCI (1.01-3.22), 1.13 for late MCI (1.05-11.70), 1.21 for AD (1.09-54.05), and 1.13 for composite dementia (MCI or AD; 1.06-11.59) (ps < 0.05, F-statistics > 10). Conclusion: Higher total cholesterol may be a significant contributor to AD risk, particularly in APOE4 carriers who, based on existing literature, tend to have impaired cholesterol metabolism. Our findings highlight a possible mechanism by which APOE confers AD risk and indicate potential for AD risk modification through maintenance of healthy total cholesterol levels.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据